Literature DB >> 21048649

Cerebral venous thrombosis in Saudi Arabia. Clinical variables, response to treatment, and outcome.

Naim I Kajtazi1, Valerie A Zimmerman, Jayanthi C Arulneyam, Sadiq Y Al-Shami, Fahmi M Al-Senani.   

Abstract

OBJECTIVE: To investigate cerebral venous thrombosis (CVT) clinical presentations, risk factors, and response to treatment in Saudi Arabia.
METHODS: Retrospective analysis of the King Fahad Medical City, Riyadh, acute stroke database from April 2005 through February 2008 revealed 22 patients with CVT. Hypercoagulable work-up and neuroimaging were performed.
RESULTS: Sixteen patients were female (72.7%), and the median age was 35 years. Clinical presentations included: headache (77.3%), seizures (54.5%), focal neurological signs (54.5%), and decreased level of consciousness (50%). Over two-thirds (n=11; 69%) of female patients had a history of oral contraceptive use, which was the most common risk factor. Protein S deficiency (n=3), antiphospholipid antibody syndrome secondary to systemic lupus erythematosus (SLE) (n=1), rhinocerebral mucormycosis (n=1), leukemia (n=1), non-Hodgkin`s lymphoma (n=1), sepsis (n=1), and unknown (n=6) were causes. Affected areas included superior sagittal (n=13), transverse (n=16), sigmoid (n=14), straight (n=6), and cavernous sinus (n=1); internal cerebral vein (n=2); vein of Galen (n=3); cortical veins (n=10); and internal jugular vein (n=12). Two patients had quadriparesis, and 2 patients died. The remainder (n=18, 81.8%) improved. Bilateral hemorrhagic presentation or venous infarction, deep venous system thrombosis, and underlying malignancy had less favorable results.
CONCLUSION: Presentations in our series were similar to those in other reports, although altered consciousness and seizures were more common. Cortical vein involvement was also higher than commonly reported. Oral contraceptive use was a primary risk factor in female patients. Outcomes were favorable in 81.8% of patients.

Entities:  

Year:  2009        PMID: 21048649

Source DB:  PubMed          Journal:  Neurosciences (Riyadh)        ISSN: 1319-6138            Impact factor:   0.906


  7 in total

1.  Evaluation of cerebral venous thrombosis secondary to oral contraceptive use in adolescents.

Authors:  Hasan H Özdemir; Sefer Varol; Eşref Akıl; Abdullah Acar; Caner F Demir
Journal:  Neurol Sci       Date:  2014-08-05       Impact factor: 3.307

Review 2.  Cerebral venous thrombosis: state of the art diagnosis and management.

Authors:  Adam A Dmytriw; Jin Soo A Song; Eugene Yu; Colin S Poon
Journal:  Neuroradiology       Date:  2018-05-11       Impact factor: 2.804

3.  Nonaneurysmal Perimesencephalic Subarachnoid Hemorrhage as an Atypical Initial Presentation of Cerebral Venous Sinus Thrombosis: A Case Report.

Authors:  Roaa R Amer; Eman A Bakhsh
Journal:  Am J Case Rep       Date:  2018-04-21

Review 4.  Update on invasive fungal infections in the Middle Eastern and North African region.

Authors:  Marwan Osman; Aisha Al Bikai; Rayane Rafei; Hassan Mallat; Fouad Dabboussi; Monzer Hamze
Journal:  Braz J Microbiol       Date:  2020-07-05       Impact factor: 2.476

5.  Clinical presentations, radiological characteristics, and biological risk factors of cerebral venous thrombosis at a University Hospital in Saudi Arabia.

Authors:  Abdullah S Alamri; Mohammed F Almuaigel; Zafar Azra; Foziah J Alshamrani; Noor M AlMohish; Mona H AlSheikh
Journal:  Saudi Med J       Date:  2021-02       Impact factor: 1.484

Review 6.  Seizure in cerebral venous and sinus thrombosis.

Authors:  Jafar Mehvari Habibabadi; Mohammad Saadatnia; Nasim Tabrizi
Journal:  Epilepsia Open       Date:  2018-06-08

7.  Prevalence of cerebral venous thrombosis with the use of oral contraceptive pills during the Holy month of Ramadan.

Authors:  Mohammed AlSheef; Mastourah Alotaibi; Abdul Rehman Z Zaidi; Areej Alshamrani; Aroub Alhamidi; Syed Ziauddin A Zaidi; Noor Alanazi; Sarah Alhathlool; Ohoud Alarfaj; Mohammed AlHazzaa; Ghaydaa Kullab; Amany Alboghdadly; Amani Abu-Shaheen
Journal:  Saudi Med J       Date:  2020-10       Impact factor: 1.484

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.